Trial Profile
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 07 Nov 2023 Status changed from active, no longer recruiting to completed.
- 17 Feb 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 17 Feb 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.